Sugi Predict

Sugi Predict / Compounds / SCHEMBL173439

SCHEMBL173439

SCHEMBL173439

COC(=O)C1CN(C(=O)OC(C)(C)C)CCC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ESR2 Q92731 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ NR1H2 P55055 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ PTPN2 P17706 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ PTPN6 P29350 1/20 0.39
▸ MMP1 P03956 1/20 0.38
▸ MMP3 P08254 1/20 0.38
▸ MMP7 P09237 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ DDB1 Q16531 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017464 0.87 ALDH1A1 (0.47) ALDH1A1USP2SMN1; SMN2EPHX1KDM4E
SCHEMBL28926595 0.86 CHRNB2 (0.39) PDE4BALDH1A1SMN1; SMN2MAPT
SCHEMBL14339687 0.86 BRD4 (0.34) PDE4BALDH1A1SMN1; SMN2ESR2ADORA1
SCHEMBL5223609 0.85 USP2 (0.41) ALDH1A1USP2SMN1; SMN2ESR2ADORA1
SCHEMBL2732408 0.85 PDE4B (0.43) PDE4BALDH1A1USP2SMN1; SMN2EPHX1
SCHEMBL2123557 0.85 USP2 (0.41) ALDH1A1USP2SMN1; SMN2ESR2ADORA1
SCHEMBL183637 0.85 MAPT (0.46) ALDH1A1USP2SMN1; SMN2ESR2ADORA1
SCHEMBL29450286 0.85 MAPT (0.46) ALDH1A1USP2SMN1; SMN2ESR2ADORA1
SCHEMBL16221362 0.84 USP2 (0.41) ALDH1A1USP2SMN1; SMN2ESR2ADORA1
SCHEMBL17868613 0.84 DDB1 (0.41) ALDH1A1USP2SMN1; SMN2ESR2ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS AG (CH) 2026-04-30 — — US disclosed
WO-2026090317-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
EP-4652159-A1 INHIBITORS OF KIF18A AND USES THEREOF Insilico Medicine IP Limited (HK) 2025-11-26 — — EP disclosed
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
US-20250340569-A1 INHIBITORS OF KIF18A AND USES THEREOF INSILICO MEDICINE IP LTD (CN) 2025-11-06 — — US disclosed
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
EP-4596551-A1 COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY Trasveda Ltd. (KY) 2025-08-06 — — EP disclosed
US-20250241920-A1 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY CHIMERIX, INC. (US) 2025-07-31 — — US disclosed
CN-116283955-B Compound for targeted degradation of HDAC7, and preparation method and application thereof 浙江大学 2025-06-17 — — CN disclosed
EP-4565237-A1 PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA Chimerix, Inc. (US) 2025-06-11 — — EP disclosed
EP-0869968-A1 GROWTH-HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-10-14 — — EP disclosed
EP-0805681-A4 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1998-05-06 — — EP disclosed
EP-0805681-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1997-11-12 — — EP disclosed
US-5665719-A Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists MERCK & CO., INC. (US) 1997-09-09 — — US disclosed
WO-1997024369-A1 GROWTH-HORMONE SECRETAGOGUES PFIZER INC. (US) 1997-07-10 — — WO disclosed
WO-1996022775-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-08-01 — — WO disclosed
EP-0714299-A4 — — 1996-07-10 — — EP disclosed
EP-0714299-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-06-05 — — EP disclosed
WO-1995002405-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-01-26 — — WO disclosed
US-5376666-A Hypotensive agents, angiotension antagonist, enzyme inhibitors , treating congestive heart failure THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241920-A1 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY TPMT, PAICS, THPO PDE4B 878/4885ALDH1A1 94/4885USP2 4597/4885
US-20250340569-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF2C PDE4B 1931/4885ALDH1A1 2657/4885USP2 1987/4885
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK6 PDE4B 3620/4885ALDH1A1 2275/4885USP2 2411/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN PDE4B 1092/4885ALDH1A1 649/4885USP2 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.